Public Health England's annual 'Hepatitis C in the UK' report is the key national reporting document for hepatitis C. This is the tenth such report and follows the WHO Global Health Sector Strategy on Viral Hepatitis 2016 to 2021 and the draft action plan for the health sector response to viral hepatitis in the WHO European region. The report is structured to support UK monitoring of the Global Health Sector Strategy goals and summarises the impact of UK action plans to drive down mortality from HCV and reduce the number of new infections.
Access and Uptake of Direct Acting Antiviral Medicines in the UK and selected European countries
Download
This report, produced by IMS Health and commissioned by the Association of the British Pharmaceutical Industry (ABPI), provides information related to the uptake of Direct Acting Antiviral treatments (DAAs) over the last five years, to June 2016. The intention of the report is to benchmark the UK – in relation to patient access to these medicines – compared with other European countries. It finds that there have been significant variances in the ability of patients to access these medicines. For example, Portugal, Belgium and Germany have now treated over a quarter of their estimated prevalent patients. By contrast, the trend in the UK has been one of slower and lower levels of access.
